NEW YORK, April 17 – Luminex has licensed its LabMap technology to ARUP Laboratories, a national specialty diagnostic reference laboratory, the company said Tuesday.
Under the agreement, ARUP will use Luminex’s technology to develop clinical laboratory assays for antibodies to common disease agents, such as Streptococcus pneumoniae and mitogens. Luminex will receive royalties on the sale of these diagnostic tests.
LabMap uses microspheres to assay nucleic acids, antigen-antibody binding, enzymes, and other receptor-ligand interactions. Small lasers, digital processors, and software allow the system to perform up to 100 assays per drop of fluid.
Luminex has said its business strategy is to seek out partnerships with clinical diagnostics companies and other organizations to develop commercial applications for its technology.
"Clinical reference labs continue to search for new technologies that have the ability to expand existing testing menus while reducing internal costs and our strategic partnership with ARUP is another powerful validation of how our system can be an integral solution in the clinical industry,” John Porter, Luminex’s director of business development, said in a statement.
This announcement follows closely Luminex’s warning Monday that it has slashed revenue expectations for the first quarter of 2001, due to its partners’ delay in commercializing bioassay kits based on its technology. The company also said it had added 30 new customers for LabMap during the first quarter of 2001, bringing its installed base of LabMap systems to over 500 as of March 31.
Luminex is expected to release first-quarter final results after the close of the market next Tuesday.